As previously announced Biotime PanC-DX Breast cancer product will be a blood diagnostic test to be released first in the EU then in the US(after 6 mo evaluation) mid 2014. Lung and Bladder coming soon after.
Here are three key BTX patents protecting their cutting edge diagnostics products:
-Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.
-Defining cell-matrix combination products in the era of pluripotency.
-Identification of human embryonic progenitor cell targeting peptides using phage display.
-COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature.
-Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes.
"then in the US(after 6 mo evaluation) mid 2014. "
ROTFL.... Now that you have proven you know nothing about how the FDA works, proceed to the amusing issue--1/2 the companies in that space wiped pout shareholders before getting widely used.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today’s Discoveries – Tomorrow’s Cures.